158 related articles for article (PubMed ID: 15505099)
1. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation.
Bauer A; McDonald AD; Nasir K; Peller L; Rade JJ; Miller JM; Heldman AW; Donahue JK
Circulation; 2004 Nov; 110(19):3115-20. PubMed ID: 15505099
[TBL] [Abstract][Full Text] [Related]
2. Genetic suppression of Gαs protein provides rate control in atrial fibrillation.
Lugenbiel P; Thomas D; Kelemen K; Trappe K; Bikou O; Schweizer PA; Voss F; Becker R; Katus HA; Bauer A
Basic Res Cardiol; 2012 May; 107(3):265. PubMed ID: 22457123
[TBL] [Abstract][Full Text] [Related]
3. Focal modification of electrical conduction in the heart by viral gene transfer.
Donahue JK; Heldman AW; Fraser H; McDonald AD; Miller JM; Rade JJ; Eschenhagen T; Marbán E
Nat Med; 2000 Dec; 6(12):1395-8. PubMed ID: 11100126
[TBL] [Abstract][Full Text] [Related]
4. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model.
Bikou O; Thomas D; Trappe K; Lugenbiel P; Kelemen K; Koch M; Soucek R; Voss F; Becker R; Katus HA; Bauer A
Cardiovasc Res; 2011 Nov; 92(2):218-25. PubMed ID: 21799069
[TBL] [Abstract][Full Text] [Related]
5. Rate control in atrial fibrillation.
Van Gelder IC; Rienstra M; Crijns HJ; Olshansky B
Lancet; 2016 Aug; 388(10046):818-28. PubMed ID: 27560277
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular performance during acute rate control in atrial fibrillation: the importance of heart rate and agent used.
Pinter A; Dorian P; Paquette M; Ng A; Burns M; Spanu I; Freeman M; Korley V; Newman D
J Cardiovasc Pharmacol Ther; 2003 Mar; 8(1):17-24. PubMed ID: 12652326
[TBL] [Abstract][Full Text] [Related]
7. Creation of a genetic calcium channel blocker by targeted gem gene transfer in the heart.
Murata M; Cingolani E; McDonald AD; Donahue JK; Marbán E
Circ Res; 2004 Aug; 95(4):398-405. PubMed ID: 15242970
[TBL] [Abstract][Full Text] [Related]
8. Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant.
Soucek R; Thomas D; Kelemen K; Bikou O; Seyler C; Voss F; Becker R; Koenen M; Katus HA; Bauer A
Heart Rhythm; 2012 Feb; 9(2):265-72. PubMed ID: 21907172
[TBL] [Abstract][Full Text] [Related]
9. Impact of atrioventricular node ablation and pacing therapy on clinical course in patients with permanent atrial fibrillation and unstable ventricular tachycardia induced by rapid ventricular response: follow-up study.
Petrac D; Radićc B; Radeljić V; Hamel D; Filipović J
Croat Med J; 2005 Dec; 46(6):929-35. PubMed ID: 16342346
[TBL] [Abstract][Full Text] [Related]
10. [Permanent atrial fibrillation and heart failure: radiofrequency ablation of atrioventricular junction and cardiac resynchronization therapy: review of the literature and of the new techniques for echocardiographic assessment].
Proclemer A; Allocca G; Badano LP; Pavoni D; Baldassi M; Nucifora G; Facchin D; Fioretti PM
G Ital Cardiol (Rome); 2007 Apr; 8(4):215-24. PubMed ID: 17506293
[TBL] [Abstract][Full Text] [Related]
11. Assessment of upgrading to biventricular pacing in patients with right ventricular pacing and congestive heart failure after atrioventricular junctional ablation for chronic atrial fibrillation.
Valls-Bertault V; Fatemi M; Gilard M; Pennec PY; Etienne Y; Blanc JJ
Europace; 2004 Sep; 6(5):438-43. PubMed ID: 15294269
[TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation in congestive heart failure.
Seiler J; Stevenson WG
Cardiol Rev; 2010; 18(1):38-50. PubMed ID: 20010337
[TBL] [Abstract][Full Text] [Related]
13. Long-term survival after ablation of the atrioventricular node and implantation of a permanent pacemaker in patients with atrial fibrillation.
Ozcan C; Jahangir A; Friedman PA; Patel PJ; Munger TM; Rea RF; Lloyd MA; Packer DL; Hodge DO; Gersh BJ; Hammill SC; Shen WK
N Engl J Med; 2001 Apr; 344(14):1043-51. PubMed ID: 11287974
[TBL] [Abstract][Full Text] [Related]
14. [Digoxin and atrial fibrillation in 2016].
Théone S; Carballo S; Carballo D; Marti C
Rev Med Suisse; 2016 Oct; 12(535):1758-1760. PubMed ID: 28692216
[TBL] [Abstract][Full Text] [Related]
15. Cardiac resynchronization therapy in the setting of permanent atrial fibrillation and heart failure.
Koneru JN; Steinberg JS
Curr Opin Cardiol; 2008 Jan; 23(1):9-15. PubMed ID: 18281821
[TBL] [Abstract][Full Text] [Related]
16. [Can atrial fibrillation be managed without anti-arrhythmia drugs?].
Blanc JJ; Mansourati J
Arch Mal Coeur Vaiss; 1994 Sep; 87 Spec No 3():63-7. PubMed ID: 7786126
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous right atrioventricular pacing: a novel model to study atrial remodeling and fibrillation in the setting of heart failure.
Laurent G; Moe GW; Hu X; Pui-Sze So P; Ramadeen A; Leong-Poi H; Doumanovskaia L; Konig A; Trogadis J; Courtman D; Strauss BH; Dorian P
J Card Fail; 2008 Apr; 14(3):254-62. PubMed ID: 18381190
[TBL] [Abstract][Full Text] [Related]
18. Atrial fibrillation and heart failure: beyond the heart rate.
Garg A; Akoum N
Curr Opin Cardiol; 2013 May; 28(3):332-6. PubMed ID: 23549231
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation.
Khadjooi K; Foley PW; Chalil S; Anthony J; Smith RE; Frenneaux MP; Leyva F
Heart; 2008 Jul; 94(7):879-83. PubMed ID: 18208826
[TBL] [Abstract][Full Text] [Related]
20. Ventricular pacing vs dual chamber pacing in patients with persistent atrial fibrillation after atrioventricular node ablation: open randomized study.
Petrac D; Radić B; Radeljić V; Hamel D; Filipović J
Croat Med J; 2005 Dec; 46(6):922-8. PubMed ID: 16342345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
